Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Expert Consensus on Screening and Assessment of Cognition in Psychiatry

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Neuronal underpinnings of cognitive impairment and - improvement in mood disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

BACKGROUND: Treatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. This study aims to assess the involvement of cytokines in the therapeutic effects of liraglutide.

METHODS: Serum concentrations of 10 cytokines (interferon-γ [IFN-γ], tumor necrosis factor-α, interleukin 1β [IL-1β], IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13) from fasting prediabetic and normal glucose-tolerant (NGT) patients with schizophrenia-spectrum disorders were measured using multiplexed immunoassays. Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo, and cytokines were measured again at the end of the treatment.

RESULTS: IFN-γ (1.98 vs 1.17 pg/ml, P = .001), IL-4 (0.02 vs 0.01 pg/ml, P < .001), and IL-6 (0.73 vs 0.46 pg/ml, P < .001) were significantly higher in prediabetic (n = 77) vs NGT patients (n = 31). No significant changes in cytokine levels following treatment with liraglutide (n = 37) vs placebo (n = 40) were found.

CONCLUSION: Prediabetic vs NGT patients with schizophrenia treated with clozapine or olanzapine had increased serum levels of several proinflammatory cytokines, further substantiating the link between inflammation and T2D. Treatment with liraglutide did not affect the investigated cytokines. Further testing of these findings in larger numbers of individuals is needed.

TidsskriftCNS Spectrums
Udgave nummer3
Sider (fra-til)347-354
Antal sider8
StatusUdgivet - jun. 2022

ID: 61525025